BRPI0406692A - Implante ocular biodegradável - Google Patents

Implante ocular biodegradável

Info

Publication number
BRPI0406692A
BRPI0406692A BR0406692-8A BRPI0406692A BRPI0406692A BR PI0406692 A BRPI0406692 A BR PI0406692A BR PI0406692 A BRPI0406692 A BR PI0406692A BR PI0406692 A BRPI0406692 A BR PI0406692A
Authority
BR
Brazil
Prior art keywords
biodegradable
eye implant
implants
eye
release
Prior art date
Application number
BR0406692-8A
Other languages
English (en)
Inventor
Thierry Nivaggioli
Lin Peng
David Chou
David Weber
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to BR122015016901A priority Critical patent/BR122015016901B8/pt
Publication of BRPI0406692A publication Critical patent/BRPI0406692A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

"IMPLANTE OCULAR BIODEGRADáVEL". A presente invenção refere-se a implantes biodegradáveis talhados para implantação na região ocular e processos para tratamento de condições médicas do olho. Os implantes são formados a partir de uma mistura de PLGA de extremidade hidrofílica e hidrofóbica, e liberam agentes ativos em uma região ocular sem uma alta explosão de liberação.
BR0406692-8A 2003-01-09 2004-01-07 Implante ocular biodegradável BRPI0406692A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122015016901A BR122015016901B8 (pt) 2003-01-09 2004-01-07 implante de bioerosão para tratamento de uma condição médica do olho humano compreendendo dexametasona

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/340,237 US20040137059A1 (en) 2003-01-09 2003-01-09 Biodegradable ocular implant
PCT/US2004/000351 WO2004062649A2 (en) 2003-01-09 2004-01-07 Biodegradable ocular implant

Publications (1)

Publication Number Publication Date
BRPI0406692A true BRPI0406692A (pt) 2005-12-20

Family

ID=32711277

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0406692-8A BRPI0406692A (pt) 2003-01-09 2004-01-07 Implante ocular biodegradável
BR122015016901A BR122015016901B8 (pt) 2003-01-09 2004-01-07 implante de bioerosão para tratamento de uma condição médica do olho humano compreendendo dexametasona

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122015016901A BR122015016901B8 (pt) 2003-01-09 2004-01-07 implante de bioerosão para tratamento de uma condição médica do olho humano compreendendo dexametasona

Country Status (21)

Country Link
US (1) US20040137059A1 (pt)
EP (6) EP1581193B1 (pt)
JP (1) JP4223040B2 (pt)
KR (1) KR20050099008A (pt)
CN (2) CN101259280A (pt)
AT (1) ATE555779T1 (pt)
AU (1) AU2004204744B2 (pt)
BR (2) BRPI0406692A (pt)
CA (1) CA2512315C (pt)
CY (4) CY1118431T1 (pt)
DK (5) DK1917957T3 (pt)
ES (5) ES2742152T3 (pt)
FR (1) FR12C0067I1 (pt)
HK (1) HK1084021A1 (pt)
HU (4) HUE044694T2 (pt)
MX (1) MXPA05007342A (pt)
NZ (1) NZ540451A (pt)
PT (4) PT3187177T (pt)
SI (3) SI3305284T1 (pt)
TR (2) TR201802793T4 (pt)
WO (1) WO2004062649A2 (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CA2524271C (en) 2003-05-02 2012-09-04 Surmodics, Inc. Controlled release bioactive agent delivery device
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2005314426A1 (en) * 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2011236024B2 (en) * 2005-03-01 2013-05-23 Allergan, Inc. Microimplants for ocular administration
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
CA2680831A1 (en) * 2007-03-14 2008-09-18 University Of Washington Device and method for intraocular drug delivery
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
KR101996336B1 (ko) * 2007-09-07 2019-07-04 마티 테라퓨틱스 인코포레이티드 치료 약제의 서방성 약물 코어
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found INTRAOCULAR DRUG DELIVERY DEVICE AND ASSOCIATED METHODS
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
CN101612111B (zh) * 2008-06-24 2011-11-23 上海医药工业研究院 醋酸诺美孕酮或其类似物的缓释微球及其制备方法和用途
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
EP2464364A2 (en) * 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
CA2771154A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
EP2464365A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
AU2010282276A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
CA2771181A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
EP2464660A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
JP2013518907A (ja) 2010-02-08 2013-05-23 アラーガン インコーポレイテッド カンナビノイド−２作動薬として有用なピリダジン誘導体
US20130030055A1 (en) 2010-03-24 2013-01-31 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US20120207704A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
US20120207742A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treatments Using PSMA Ligand Endopeptidases
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
US20120207733A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
MX351261B (es) 2012-06-01 2017-10-06 Surmodics Inc Aparato y método para recubrir catéteres con globo.
US20150290170A1 (en) 2012-10-26 2015-10-15 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
CN105142710A (zh) * 2013-01-15 2015-12-09 科罗拉多州立大学董事会,公司实体 泪腺系统给药装置
EP2968886A1 (en) 2013-03-14 2016-01-20 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
DK3062775T3 (en) * 2013-10-31 2018-03-12 Allergan Inc PROSTAMID-CONTAINING INTRAOCULAR IMPLANTS AND PROCEDURES FOR USE THEREOF
CA2939651A1 (en) * 2014-02-26 2015-09-03 Allergan, Inc. Intraocular implant delivery apparatus and methods of use thereof
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CN106687080A (zh) 2014-09-11 2017-05-17 普西维达公司 注射器设备
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
USD851755S1 (en) 2015-10-22 2019-06-18 Eyepoint Pharmaceuticals Us, Inc. Ocular inserter
CA3006042A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
AU2017252294B2 (en) 2016-04-20 2021-12-02 Dose Medical Corporation Bioresorbable ocular drug delivery device
CA3024912A1 (en) 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
EP0052916B1 (en) * 1980-11-10 1985-01-02 Alza Corporation Erodible polymer containing erosion rate modifier
US4883457A (en) * 1983-08-18 1989-11-28 Drug Delivery Systems Inc. Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JPS63291419A (ja) * 1987-05-24 1988-11-29 Tatsumo Kk 加熱処理装置
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
KR100313268B1 (ko) 1993-02-26 2002-11-22 산텐 세이야꾸 가부시키가이샤 생체분해성공막플러그
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
JPH11509862A (ja) * 1996-01-24 1999-08-31 アメリカ合衆国 新規「バーストフリー」持続放出型ポリ（ラクチド／グリコリド）微小球
WO1999001156A1 (fr) * 1997-07-02 1999-01-14 Santen Pharmaceutical Co., Ltd. Bouchons scleraux d'acide polylactique
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2250504T3 (es) * 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.

Also Published As

Publication number Publication date
SI3187177T1 (sl) 2019-09-30
ATE555779T1 (de) 2012-05-15
CY1121731T1 (el) 2020-07-31
EP2799064A1 (en) 2014-11-05
WO2004062649A2 (en) 2004-07-29
ES2742152T3 (es) 2020-02-13
AU2004204744B2 (en) 2008-03-13
DK3187177T3 (da) 2019-06-24
TR201908857T4 (tr) 2019-07-22
ES2661383T3 (es) 2018-03-28
TR201802793T4 (tr) 2018-03-21
US20040137059A1 (en) 2004-07-15
JP2006525953A (ja) 2006-11-16
MXPA05007342A (es) 2005-09-30
PT2799064T (pt) 2018-03-06
AU2004204744A1 (en) 2004-07-29
EP1917957A2 (en) 2008-05-07
EP1581193B1 (en) 2012-05-02
SI2799064T1 (en) 2018-04-30
NZ540451A (en) 2008-02-29
KR20050099008A (ko) 2005-10-12
EP1581193A2 (en) 2005-10-05
CY1121912T1 (el) 2020-10-14
CA2512315A1 (en) 2004-07-29
JP4223040B2 (ja) 2009-02-12
BR122015016901B8 (pt) 2021-07-27
FR12C0067I1 (fr) 2012-12-14
EP3305284A1 (en) 2018-04-11
PT3187177T (pt) 2019-06-27
PT3305284T (pt) 2019-08-30
HUE030319T2 (en) 2017-05-29
EP1917957B1 (en) 2016-11-16
WO2004062649A3 (en) 2004-11-04
BR122015016901B1 (pt) 2018-06-05
ES2735132T3 (es) 2019-12-16
CY1120147T1 (el) 2018-12-12
DK1581193T3 (da) 2012-06-25
HUE044694T2 (hu) 2019-11-28
CN1735405A (zh) 2006-02-15
DK1917957T3 (en) 2017-02-13
DK2799064T3 (en) 2018-03-12
ES2384875T3 (es) 2012-07-13
PT1917957T (pt) 2017-01-23
EP3187177B1 (en) 2019-03-20
EP2799064B1 (en) 2017-11-29
CY1118431T1 (el) 2017-06-28
HUE044965T2 (hu) 2019-11-28
EP1917957A3 (en) 2011-06-15
HUE036209T2 (hu) 2018-06-28
HK1084021A1 (en) 2006-07-21
SI3305284T1 (sl) 2019-11-29
DK3305284T3 (da) 2019-08-19
ES2613028T3 (es) 2017-05-22
CA2512315C (en) 2008-12-30
EP3305284B1 (en) 2019-05-15
EP3563839A1 (en) 2019-11-06
CN100364514C (zh) 2008-01-30
CN101259280A (zh) 2008-09-10
EP3187177A1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
BRPI0406692A (pt) Implante ocular biodegradável
BRPI0513849B8 (pt) implante ocular fabricado por um processo de extrusão dupla
Baino Biomaterials and implants for orbital floor repair
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
WO2010059214A3 (en) Biocompatible biodegradable intraocular implant system
MD3247F1 (ro) Metoda de tratament al cataractei senile
WO2004069335A3 (en) Magnetic implants to treat body tissue structures
RU2012133880A (ru) Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента
KR20130138218A (ko) 대퇴비구 충돌 수술 시에 사용하기 위한 임플란트, 수술 방법, 및 도구
CA2656523A1 (en) Flexible bioresorbable hemostatic packing and stent
BRPI0607483A2 (pt) microimplantes para administração ocular
WO2001070289A3 (en) Injectable and swellable microspheres for tissue bulking
ATE195065T1 (de) Biologisch abbaubarer sklerastopfen
JP2013520239A (ja) 網膜を再構成するための最小限侵襲方法及び装置
WO2019169835A1 (zh) 一种泪小管栓
CA2396130A1 (en) Preparation of irrigating solution for ocular surgery
Jordan et al. Controversies in enucleation technique and implant selection: whether to wrap, attach muscles, and peg?
RU99126213A (ru) Способ хирургического лечения болезни трансплантата роговицы
RU2000119720A (ru) Способ предотвращения дислокации силикона в переднюю камеру при хирургическом лечении рецидивирующих отслоек сетчатки
UA40313A (uk) Спосіб видалення підвивихнутого кришталика з наступною імплантацією штучного кришталика

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]